Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
International Journal of Molecular Sciences · 15.02.2025 · 26 (4) · 1670
DOI: 10.3390/ijms26041670 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2025. Verfasst von Elena Y Rykova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (IC&G SB RAS), Lavrentjev Prospect 10, 630090 Novosibirsk, Russia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Macrophages, Anti-Inflammatory Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
A growing body of evidence indicates that nonglycemic effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors play an important role in the protective effects of these drugs in diabetes, chronic kidney disease, and heart failure. In recent years, the anti-inflammatory potential of SGLT2 inhibitors has been actively studied. This review summarizes results of clinical and experimental studies on the anti-inflammatory activity of SGLT2 inhibitors, with a special focus on their effects on macrophages, key drivers of metabolic inflammation. In patients with type 2 diabetes, therapy with SGLT2 inhibitors reduces levels of inflammatory mediators. In diabetic and non-diabetic animal models, SGLT2 inhibitors control low-grade inflammation by suppressing inflammatory activation of tissue macrophages, recruitment of monocytes from the bloodstream, and macrophage polarization towards the M1 phenotype. The molecular mechanisms of the effects of SGLT2 inhibitors on macrophages include an attenuation of inflammasome activity and inhibition of the TLR4/NF-κB pathway, as well as modulation of other signaling pathways (AMPK, PI3K/Akt, ERK 1/2-MAPK, and JAKs/STAT). The review discusses the state-of-the-art concepts and prospects of further investigations that are needed to obtain a deeper insight into the mechanisms underlying the effects of SGLT2 inhibitors on the molecular, cellular, and physiological levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (IC&G SB RAS), Lavrentjev Prospect 10, 630090 Novosibirsk, Russia.
- Research Institute of Clinical and Experimental Lymphology, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (RICEL-Branch of IC&G SB RAS), Timakov Str. 2, 630060 Novosibi…
- Laboratory of Translational Cellular and Molecular Biomedicine, National Research Tomsk State University, 634050 Tomsk, Russia.
- Institute of Transfusion Medicine and Immunology, Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
ORCID-Profile: Vadim V Klimontov, Elena Shmakova, Anton I Korbut, Julia Kzhyshkowska
Förderung
- Russian Science Foundation
Zitieren
APA
Rykova, E. Y., Klimontov, V. V., Shmakova, E., Korbut, A. I., Merkulova, T. I., & Kzhyshkowska, J. (2025). Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages. International Journal of Molecular Sciences, 26(4), 1670. https://doi.org/10.3390/ijms26041670
Vancouver
Rykova EY, Klimontov VV, Shmakova E, Korbut AI, Merkulova TI, Kzhyshkowska J. Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages. International Journal of Molecular Sciences. 2025;26(4):1670. doi:10.3390/ijms26041670
BibTeX
@article{Rykova2025,
author = {Rykova, Elena Y and Klimontov, Vadim V and Shmakova, Elena and Korbut, Anton I and Merkulova, Tatyana I and Kzhyshkowska, Julia},
title = {Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {4},
pages = {1670},
doi = {10.3390/ijms26041670}
}
EUVIMED